In our previous work, we demonstrated that increased HSP90 levels correlate with negative outcomes in chronic myeloid leukemia (CML) course and response to therapy [32]. The gene discussed is HSP90AB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.